Covid-19 Generic Drug
- All
- News
- Videos
-
Hyderabad Firm Seeks Approval To Produce Generic Merck Covid Pill
The bulk drugs manufacturer Optimus Pharma is seeking domestic regulatory approval to produce a generic version of Merck & Co's oral COVID-19 treatment molnupiravir, the company's top executive told Reuters on Thursday.
-
Merck COVID-19 Pill Has Vital Indian Link, Maker Sees Stock Price Jump
India's Everest Organics Ltd said on Tuesday it had started making the active pharmaceutical ingredient (API) for a generic version of Merck & Co's experimental antiviral drug molnupiravir to treat mild to moderate COVID-19.
-
Hetero Gets Emergency Use Nod For Generic Version Of Covid Drug Tocilizumab
Indian drug developer Hetero said on Monday it has received emergency use approval from the country's health authorities to make a generic version of Roche Holding AG's COVID-19 drug.
-
1st Covid Vaccine For Children Above 12 Approved In India
India's drug regulator on Friday approved Zydus Cadila's three-dose COVID-19 DNA vaccine for emergency use in adults and children aged 12 years and above, bringing in the sixth vaccine authorised for use in the country.
-
3 Indian Firms To Make, Sell US's Eli Lilly's Baricitinib Drug For Covid Treatment
Eli Lilly and Co said on Monday it had signed licensing agreements with three Indian generic drugmakers to expand the availability of its arthritis drug baricitinib in the country for treating COVID-19 patients.
-
Merck Taps 5 Indian Drugmakers To Expand Covid Drug Production
Merck & Co Inc said on Tuesday it had partnered with five Indian generic drugmakers, including Cipla Ltd and Sun Pharmaceutical Industries Ltd, to expand production and access to its experimental COVID-19 drug.
-
Zydus Cadila Launches India's Cheapest Remdesivir Version At Rs 2,800 Per Vial
It (Remdesivir version) will be sold under the brand name Remdac to government and private hospitals treating Covid-19 patients, the company said in a regulatory filing.
-
India's Shortage Of Remdesivir Is Easing, Says Producer Cipla
India's supply of antiviral drug remdesivir and generic equivalents is stabilising after shortages of the vital COVID-19 medicine at hospitals, according to a top executive at one of the country's big drugmakers, Cipla Ltd.
-
India On Fast-Track Mode To Develop COVID-19 Vaccine: Top Medical Body
India is considered as the "pharmacy of the world". About 60 per cent of the drugs uitilised in the United States of America are of Indian origin. So, these are generic drugs produced in India where the country has established itself over the years. This is possibly well known to many people in the world, said (Prof) Dr Balram Bhargava, Director Ge...
-
Maharashtra, Delhi Among 5 States To Receive First Batch Of COVID-19 Drug
Hyderabad-based drugmaker Hetero, which has approval to manufacture and market the generic version of the experimental COVID-19 drug Remdesivir, has sent 20,000 vials to five states including Maharashtra and Delhi - the two worst affected states in the country.
-
Hyderabad-Based Hetero Prices Generic COVID-19 Drug At Rs 5,400 Per Vial
Hyderabad-based Hetero Labs Ltd has priced its generic version of remdesivir, Gilead's experimental COVID-19 drug, at Rs 5,400 ($71) per 100-milligram vial, the drug maker said on Wednesday, as it prepares to ship them to hospitals in the country.
-
No Game Changers: Medical Experts On Remdesiver, Favipiravir For COVID Treatment
With pharmaceutical companies launching generic versions of Remdesivir and Favipiravir for COVID-19 treatment, medical experts on Monday said it was a "positive development" in the fight against the pandemic, but cautioned against regarding the antiviral drugs as "game changers".
-
Cipla Gets Regulatory Nod To Make Gilead's COVID-19 Drug, Shares Hit Record High
Cipla shares surged over 9% after it got an approval from DCGI to manufacture and market generic COVID-19 drug Remdesivir.
-
Hyderabad-Based Hetero Gets Regulatory Nod To Make Gilead's COVID-19 Drug
Hetero said its generic version of US-based Gilead Science's Remdesivir will be marketed under brand name Covifor in India.
-
A Cheap Steroid Emerges As Life-Saving Drug For COVID-19
Giving low doses of the generic steroid drug dexamethasone to patients admitted to hospital with COVID-19 reduced death rates by around a third among those with the most severe cases of infection, trial data showed on Tuesday.
-
Hyderabad Firm Seeks Approval To Produce Generic Merck Covid Pill
The bulk drugs manufacturer Optimus Pharma is seeking domestic regulatory approval to produce a generic version of Merck & Co's oral COVID-19 treatment molnupiravir, the company's top executive told Reuters on Thursday.
-
Merck COVID-19 Pill Has Vital Indian Link, Maker Sees Stock Price Jump
India's Everest Organics Ltd said on Tuesday it had started making the active pharmaceutical ingredient (API) for a generic version of Merck & Co's experimental antiviral drug molnupiravir to treat mild to moderate COVID-19.
-
Hetero Gets Emergency Use Nod For Generic Version Of Covid Drug Tocilizumab
Indian drug developer Hetero said on Monday it has received emergency use approval from the country's health authorities to make a generic version of Roche Holding AG's COVID-19 drug.
-
1st Covid Vaccine For Children Above 12 Approved In India
India's drug regulator on Friday approved Zydus Cadila's three-dose COVID-19 DNA vaccine for emergency use in adults and children aged 12 years and above, bringing in the sixth vaccine authorised for use in the country.
-
3 Indian Firms To Make, Sell US's Eli Lilly's Baricitinib Drug For Covid Treatment
Eli Lilly and Co said on Monday it had signed licensing agreements with three Indian generic drugmakers to expand the availability of its arthritis drug baricitinib in the country for treating COVID-19 patients.
-
Merck Taps 5 Indian Drugmakers To Expand Covid Drug Production
Merck & Co Inc said on Tuesday it had partnered with five Indian generic drugmakers, including Cipla Ltd and Sun Pharmaceutical Industries Ltd, to expand production and access to its experimental COVID-19 drug.
-
Zydus Cadila Launches India's Cheapest Remdesivir Version At Rs 2,800 Per Vial
It (Remdesivir version) will be sold under the brand name Remdac to government and private hospitals treating Covid-19 patients, the company said in a regulatory filing.
-
India's Shortage Of Remdesivir Is Easing, Says Producer Cipla
India's supply of antiviral drug remdesivir and generic equivalents is stabilising after shortages of the vital COVID-19 medicine at hospitals, according to a top executive at one of the country's big drugmakers, Cipla Ltd.
-
India On Fast-Track Mode To Develop COVID-19 Vaccine: Top Medical Body
India is considered as the "pharmacy of the world". About 60 per cent of the drugs uitilised in the United States of America are of Indian origin. So, these are generic drugs produced in India where the country has established itself over the years. This is possibly well known to many people in the world, said (Prof) Dr Balram Bhargava, Director Ge...
-
Maharashtra, Delhi Among 5 States To Receive First Batch Of COVID-19 Drug
Hyderabad-based drugmaker Hetero, which has approval to manufacture and market the generic version of the experimental COVID-19 drug Remdesivir, has sent 20,000 vials to five states including Maharashtra and Delhi - the two worst affected states in the country.
-
Hyderabad-Based Hetero Prices Generic COVID-19 Drug At Rs 5,400 Per Vial
Hyderabad-based Hetero Labs Ltd has priced its generic version of remdesivir, Gilead's experimental COVID-19 drug, at Rs 5,400 ($71) per 100-milligram vial, the drug maker said on Wednesday, as it prepares to ship them to hospitals in the country.
-
No Game Changers: Medical Experts On Remdesiver, Favipiravir For COVID Treatment
With pharmaceutical companies launching generic versions of Remdesivir and Favipiravir for COVID-19 treatment, medical experts on Monday said it was a "positive development" in the fight against the pandemic, but cautioned against regarding the antiviral drugs as "game changers".
-
Cipla Gets Regulatory Nod To Make Gilead's COVID-19 Drug, Shares Hit Record High
Cipla shares surged over 9% after it got an approval from DCGI to manufacture and market generic COVID-19 drug Remdesivir.
-
Hyderabad-Based Hetero Gets Regulatory Nod To Make Gilead's COVID-19 Drug
Hetero said its generic version of US-based Gilead Science's Remdesivir will be marketed under brand name Covifor in India.
-
A Cheap Steroid Emerges As Life-Saving Drug For COVID-19
Giving low doses of the generic steroid drug dexamethasone to patients admitted to hospital with COVID-19 reduced death rates by around a third among those with the most severe cases of infection, trial data showed on Tuesday.
